X4 Pharmaceuticals (XFOR) to Release Earnings on Wednesday

X4 Pharmaceuticals (NASDAQ:XFOR) will be issuing its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The firm had revenue of $3.43 million during the quarter. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

X4 Pharmaceuticals Trading Up 0.1 %

XFOR opened at $0.62 on Monday. The stock has a market cap of $104.05 million, a PE ratio of 7.72 and a beta of 0.39. The company has a quick ratio of 6.04, a current ratio of 6.07 and a debt-to-equity ratio of 0.79. X4 Pharmaceuticals has a twelve month low of $0.47 and a twelve month high of $1.60. The company has a fifty day moving average of $0.60 and a 200-day moving average of $0.77.

Insiders Place Their Bets

In related news, CFO Adam S. Mostafa sold 230,645 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, COO Mary Dibiase sold 67,695 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the transaction, the chief operating officer now owns 452,060 shares in the company, valued at approximately $257,674.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 580,800 shares of company stock worth $321,447. Company insiders own 1.62% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.